Related Experiment Videos
DSP-4 lesioning prevents the enhancement of dopamine and 5-hydroxytryptamine mediated behavioural changes by repeated
Abstract:
DSP-4 (N-(2-chloroethyl)-ethyl-2-bromobenzylamine) a novel neurotoxin which destroys central noradrenaline neurones after peripheral injection was administered to rats (50 mg/kg X 2). This procedure did not alter activity responses to quipazine (7.5 mg/kg) or apomorphine (0.2 mg/kg) but prevented their enhancement by repeated electroconvulsive shocks (ECS X 10). This confirms that intact noradrenergic function is required for ECS-induced enhancement of 5-HT and dopamine mediated responses. Furthermore, DSP-4 is shown to provide a simple, effective alternative to centrally injected 6-hydroxydopamine for noradrenergic lesioning.
Insights
DSP-4 neurotoxin administration in rats confirmed intact noradrenergic function is required for electroconvulsive shock (ECS) enhancement of serotonin and dopamine responses. DSP-4 offers an effective alternative for noradrenergic lesioning.
Area of Science:
- Neuroscience
- Pharmacology
- Neurotoxicology
Background:
- Noradrenaline (NA) pathways are crucial for modulating behavioral responses to various neurochemicals.
- Electroconvulsive shocks (ECS) are known to enhance certain neurochemical-mediated behaviors.
- The role of intact noradrenergic function in ECS-induced behavioral modifications requires further elucidation.
Purpose of the Study:
- To investigate the necessity of intact noradrenergic function for ECS-induced enhancement of dopamine and serotonin-mediated responses.
- To evaluate DSP-4 as a peripheral agent for creating noradrenergic lesions in rats.
- To compare DSP-4 with traditional neurotoxins like 6-hydroxydopamine.
Main Methods:
- Rats were administered DSP-4 (N-(2-chloroethyl)-ethyl-2-bromobenzylamine) peripherally to induce noradrenergic neurotoxicity.
- Behavioral responses to quipazine (serotonin agonist) and apomorphine (dopamine agonist) were assessed.
- The effects of repeated electroconvulsive shocks (ECS) on these responses were examined in both DSP-4 treated and control groups.
Main Results:
- DSP-4 administration successfully lesioned central noradrenaline neurones without altering baseline responses to quipazine or apomorphine.
- DSP-4 treatment prevented the enhancement of quipazine and apomorphine responses typically induced by repeated ECS.
- DSP-4 proved to be an effective alternative to centrally administered 6-hydroxydopamine for noradrenergic lesioning.
Conclusions:
- Intact noradrenergic neurotransmission is essential for the behavioral enhancements observed after repeated ECS.
- DSP-4 is a valuable tool for selectively targeting noradrenergic pathways, offering a simpler and effective method for neurotoxic lesioning.
- These findings advance our understanding of the neurobiological mechanisms underlying ECS effects and provide a novel research methodology.